Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., a biotechnology company in Israel, says that immunotherapy has not always been accepted as having a high potential to successfully treat cancer. Immunotherapy was widely reported to be a potential cure for cancer in the late 1980's. Dr. Michael Har-Noy notes that this publicity motivated many companies to invest in various immunotherapy approaches throughout the late 1980's and early 1990's. During the early 2000's, much of the research done involving immunotherapy was publicized and was highly disappointing. Many high profile failures of early immunotherapy approaches in late stage clinical trials tainted the oncology community and scared off many large venture capital firms. Dr. Michael Har-Noy notes that it was widely accepted in these circles that immunotherapy was not suitable for treatment of cancer and had no real future in the treatment of the disease. Scientists thought that immunotherapy had very weak, if any, activity against cancer. Therefore, says Dr. Michael Har-Noy, it was thought that the only chance immunotherapy had to enter clinical practice was to treat minimal residual disease. However, the drug development process for new classes of drugs requires activity in late stage disease where no treatment options exist prior to testing earlier in the disease process. This combination of events, says Dr. Michael Har-Noy, resulted in very little investment and advancement of immunotherapy into the 2000's. Later, success with monoclonal antibodies and checkpoint inhibitors rekindled the enthusiasm for immunotherapy. Today, says Dr. Michael Har-Noy, cancer immunotherapy is a multi-billion dollar industry and likely represents the future of cancer treatment.